Aquestive Therapeutics, Inc. (AQST) has a negative trailing P/E of -6.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 55.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -16.45%, forward earnings yield 1.81%. PEG 0.07 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 42/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -41.0 | 0.00 | -22.37 | 7.59 | - |
| 2017 | -35.9 | -2.33 | -12.12 | 4.80 | - |
| 2018 | -2.1 | 0.00 | 12.95 | 1.94 | - |
| 2019 | -2.2 | 0.73 | -24.11 | 2.81 | - |
| 2020 | -3.2 | 0.08 | -3.71 | 3.93 | - |
| 2021 | -2.1 | -0.18 | -1.80 | 2.91 | - |
| 2022 | -0.8 | 0.02 | -0.37 | 0.92 | - |
| 2023 | -15.7 | 0.18 | -1.16 | 2.45 | - |
| 2024 | -7.0 | -0.02 | -5.13 | 5.36 | - |
| 2025 | -9.4 | -0.19 | -23.41 | 17.69 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.39 | $51.79M | $-9.6M | -18.5% |
| 2017 | $-0.45 | $66.92M | $-8.94M | -13.4% |
| 2018 | $-2.96 | $67.43M | $-61.38M | -91% |
| 2019 | $-2.87 | $52.61M | $-72.66M | -138.1% |
| 2020 | $-1.94 | $45.85M | $-65.36M | -142.6% |
| 2021 | $-2.36 | $50.83M | $-90.04M | -177.1% |
| 2022 | $-1.24 | $47.68M | $-60.2M | -126.3% |
| 2023 | $-0.13 | $50.58M | $-7.87M | -15.6% |
| 2024 | $-0.51 | $57.56M | $-44.14M | -76.7% |
| 2025 | $-0.76 | $44.55M | $-83.78M | -188.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.47 | $-0.53 – $-0.38 | $48.07M | $45.47M – $50.25M | 5 |
| 2027 | $-0.45 | $-0.64 – $-0.08 | $71.85M | $60.86M – $91.79M | 4 |
| 2028 | $-0.26 | $-0.46 – $0.10 | $109.6M | $93.33M – $139.14M | 3 |
| 2029 | $0.08 | $0.06 – $0.10 | $185.87M | $158.29M – $235.97M | 1 |
| 2030 | $0.66 | $0.53 – $0.89 | $346.92M | $295.44M – $440.43M | 1 |
